- Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- December 17, 2024
- Pfizer Declares First-Quarter 2025 Dividend
- December 12, 2024
- Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- December 12, 2024
- Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- December 10, 2024
- Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
- December 10, 2024
- Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
- December 5, 2024
- Pfizer Announces New Chief Scientific Officer and President, Research & Development
- November 20, 2024
- European Commission Approves Pfizer's HYMPAVZITM (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
- November 20, 2024
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- November 14, 2024
- Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
- October 29, 2024
- Advisory Committee on Immunization Practices Recommends PREVNAR® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
- October 23, 2024
- U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
- October 22, 2024
- Tim Buckley Elected to Pfizer's Board of Directors
- October 15, 2024
- U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
- October 11, 2024
- Pfizer's TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Triald
- October 10, 2024